
CLAIMS

~~What is claimed is:~~

1. A pharmaceutical combination ~~for treating lymphoma~~ comprising a therapeutically effective amount of a histone deacetylase 6 (HDAC6) specific inhibitor or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an immunomodulatory drug (IMiD) or a pharmaceutically acceptable salt thereof; for use in treating lymphoma.

2. The combination for the use of claim 1, wherein the HDAC6 specific inhibitor is a compound of Formula I:



(I)

or a pharmaceutically acceptable salt thereof,

wherein,


ring B is aryl or heteroaryl;

R_1 is an aryl or heteroaryl, each of which may be optionally substituted by OH, halo, or C_{1-6}-alkyl;

and


R is H or C_{1-6}-alkyl.

3. The combination for the use of claim 2, wherein the compound of Formula I is:




or a pharmaceutically acceptable salt thereof.

4. The combination for the use of claim 2, wherein the compound of Formula I is:



or a pharmaceutically acceptable salt thereof.

5. The combination for the use of claim 1, wherein the HDAC6 specific inhibitor is a compound of Formula II:



(II)

or a pharmaceutically acceptable salt thereof,


wherein,

R_x and R_y together with the carbon to which each is attached, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl;

each R_A is independently $C_{1\text{-}6}$-alkyl, $C_{1\text{-}6}$-alkoxy, halo, OH, $-NO_2$, -CN, or $-NH_2$; and


m is 0 or 1.

6. The combination for the use of claim 5, wherein the compound of Formula II is:




or a pharmaceutically acceptable salt thereof.

7. The combination for the use of claim 5, wherein the compound of Formula II is:



or a pharmaceutically acceptable salt thereof.

8. The combination for the use of claim 1, wherein the immunomodulatory drug is a compound of Formula III:



(III)


or a pharmaceutically acceptable salt thereof,

wherein,

one of X and Y is C=O, the other of X and Y is CH_2 or C=O; and


R^2 is H or C_{1-6}-alkyl.

9. The combination for the use of claim 8, wherein the compound of Formula III is:



or a pharmaceutically acceptable salt thereof.


10. The combination for the use of claim 8, wherein the compound of Formula III is:



or a pharmaceutically acceptable salt thereof.

11. ~~A method for treating lymphoma in a subject in need thereof comprising administering to the subject~~ Use of a therapeutically effective amount of ~~a pharmaceutical combination comprising~~ a histone deacetylase 6 (HDAC6) specific inhibitor or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an immunomodulatory drug (IMiD) or a pharmaceutically acceptable salt thereof; in the preparation of a pharmaceutical combination for treating lymphoma in a subject, wherein the pharmaceutical combination is for administration to the subject.

12. The ~~method~~use of claim 11, wherein the HDAC6 specific inhibitor is a compound of Formula I:



(I)

or a pharmaceutically acceptable salt thereof,

wherein,


ring B is aryl or heteroaryl;

R_1 is an aryl or heteroaryl, each of which may be optionally substituted by OH, halo, or C_{1-6}-alkyl;

and


R is H or C_{1-6}-alkyl.

13. The ~~method~~use of claim 12, wherein the compound of Formula I is:




or a pharmaceutically acceptable salt thereof.

14. The ~~method~~use of claim 12, wherein the compound of Formula I is:



or a pharmaceutically acceptable salt thereof.

15. The ~~method~~use of claim 11, wherein the HDAC6 specific inhibitor is a compound of Formula II:



(II)

or a pharmaceutically acceptable salt thereof,


wherein,

R_x and R_y together with the carbon to which each is attached, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl;

each R_A is independently $C_{1\text{-}6}$-alkyl, $C_{1\text{-}6}$-alkoxy, halo, OH, $-NO_2$, -CN, or $-NH_2$; and


m is 0 or 1.

16. The ~~method~~use of claim 15, wherein the compound of Formula II is:




or a pharmaceutically acceptable salt thereof.

17. The ~~method~~ use of claim 15, wherein the compound of Formula II is:



or a pharmaceutically acceptable salt thereof.

18. The ~~method~~use of claim 11, wherein the immunomodulatory drug is a compound of Formula III:



(III)


or a pharmaceutically acceptable salt thereof,

wherein,

one of X and Y is C=O, the other of X and Y is CH_2 or C=O; and


R^2 is H or C_{1-6}-alkyl.

19. The ~~method~~use of claim 18, wherein the compound of Formula III is:



or a pharmaceutically acceptable salt thereof.

20. The ~~method~~use of claim 18, wherein the compound of Formula III is:



or a pharmaceutically acceptable salt thereof.

21. The ~~method~~use of claim 11, wherein the subject was previously refractory to an immunomodulatory drug.

22. The ~~method~~use of claim 11, wherein the HDAC inhibitor and the immunomodulatory drug are for administer~~ed~~ation in separate dosage forms.

23. The ~~method~~use of claim 11, wherein the HDAC inhibitor and the immunomodulatory drug are for administer~~ed~~ation in a single dosage form.

24. The ~~method~~use of claim 11, wherein the HDAC inhibitor and the immunomodulatory drug are administered at different times.

25. The ~~method~~use of claim 11, wherein the HDAC inhibitor and the immunomodulatory drug administered at substantially the same time.

26. An *in vitro* method for decreasing cell cycle progression comprising administering a combination comprising an HDAC inhibitor and an immunomodulatory drug.

27. An *in vitro* method for increasing cellular apoptosis comprising administering a combination comprising an HDAC inhibitor and an immunomodulatory drug.

28. Use of ~~A method for suppressing transcriptional regulators in cancer comprising administering a combination comprising~~ an HDAC inhibitor and an immunomodulatory drug in the preparation of a pharmaceutical combination for suppressing transcriptional regulators in cancer.

29. Use of an HDAC inhibitor and an immunomodulatory drug in the preparation of a pharmaceutical combination for decreasing cell progression in a subject.

30. Use of an HDAC inhibitor and an immunomodulatory drug in the preparation of a pharmaceutical combination for increasing cellular apoptosis in a subject.